Seqirus receives FDA approval of Afluria Quadrivalent (influenza vaccine) for people six months of age and older in the U.S.


17 October 2018 - Seqirus today announced the U.S. FDA has approved Afluria Quadrivalent (influenza vaccine) for use in people six months of age and older,  extending the company's broad portfolio of influenza vaccine offerings. 

The approval also applies to the trivalent formulation of Afluria (Influenza Vaccine).

Afluria Quadrivalent was first approved in the U.S. in August 2016, for adults aged 18 years and above and helps protect against two influenza A strain viruses and two B strain viruses.

Read Seqiris press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Vaccine , Influenza